Cargando…
Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections
Table III summarizes clinical applications of antiviral agents in respiratory viral infections. For influenza A virus infections, both oral amantadine and rimantadine are effectvive when used for seasonal prophylaxis and for prophylaxis in institutional populations. Both of these drugs, as well as a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsivier Science Publishers B.V. (Biomedical Division). Published by Elsevier B.V.
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134039/ https://www.ncbi.nlm.nih.gov/pubmed/2412490 http://dx.doi.org/10.1016/S0166-3542(85)80033-4 |
_version_ | 1783517752014667776 |
---|---|
author | Hayden, Frederick G. |
author_facet | Hayden, Frederick G. |
author_sort | Hayden, Frederick G. |
collection | PubMed |
description | Table III summarizes clinical applications of antiviral agents in respiratory viral infections. For influenza A virus infections, both oral amantadine and rimantadine are effectvive when used for seasonal prophylaxis and for prophylaxis in institutional populations. Both of these drugs, as well as aerosilized ribavirin, have antiviral and therapeutic effects in uncomplicated influenza. It remains to be determined whether any of these modalities or possibly their combined use [44] will be useful in treating severe influenza in hospitalized patients or whether they can prevent the development of complications in high risk patients. Unfortunately, there is no parenteral formulation of amantadine or rimantadine for use in critically in patients. Aerosolized ribavirin has also been shown to have modest therapeutic effects in influenza B virus infection. However, a major need exists for an antiviral which is active against influenza B virus and which can be used on an outpatient basis. Controlled clinical trials have shown that aerosolized ribavirin therapy improves arterial oxygenation and modifies the severity fo respiratory syncytil virus bronchiolitis and pneumonia [3,5]. Its role in treatinglife-threatening disease or in dodifying the long-term sequelae of RSV infections are unknown at the present time. Again, a specific antiviral agent is needed for out-patient use in preventing or treating RSV infections. Finally, after over a decade of work since the original observation that intranasal interferon could prevent experimental rhinoirus infection [11], recent studies have established that intranasal rIFN-a2 is effective in the postexposure prophylaxis of rhinovirus colds in families [42]. This strategy needs to be studied with regard to the prevention of infection and its complications in high risk patients and it remains to be determined whether intranasal interferen will have therapeutic activity in established colds. |
format | Online Article Text |
id | pubmed-7134039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1985 |
publisher | Elsivier Science Publishers B.V. (Biomedical Division). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71340392020-04-08 Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections Hayden, Frederick G. Antiviral Res Article Table III summarizes clinical applications of antiviral agents in respiratory viral infections. For influenza A virus infections, both oral amantadine and rimantadine are effectvive when used for seasonal prophylaxis and for prophylaxis in institutional populations. Both of these drugs, as well as aerosilized ribavirin, have antiviral and therapeutic effects in uncomplicated influenza. It remains to be determined whether any of these modalities or possibly their combined use [44] will be useful in treating severe influenza in hospitalized patients or whether they can prevent the development of complications in high risk patients. Unfortunately, there is no parenteral formulation of amantadine or rimantadine for use in critically in patients. Aerosolized ribavirin has also been shown to have modest therapeutic effects in influenza B virus infection. However, a major need exists for an antiviral which is active against influenza B virus and which can be used on an outpatient basis. Controlled clinical trials have shown that aerosolized ribavirin therapy improves arterial oxygenation and modifies the severity fo respiratory syncytil virus bronchiolitis and pneumonia [3,5]. Its role in treatinglife-threatening disease or in dodifying the long-term sequelae of RSV infections are unknown at the present time. Again, a specific antiviral agent is needed for out-patient use in preventing or treating RSV infections. Finally, after over a decade of work since the original observation that intranasal interferon could prevent experimental rhinoirus infection [11], recent studies have established that intranasal rIFN-a2 is effective in the postexposure prophylaxis of rhinovirus colds in families [42]. This strategy needs to be studied with regard to the prevention of infection and its complications in high risk patients and it remains to be determined whether intranasal interferen will have therapeutic activity in established colds. Elsivier Science Publishers B.V. (Biomedical Division). Published by Elsevier B.V. 1985 2012-02-26 /pmc/articles/PMC7134039/ /pubmed/2412490 http://dx.doi.org/10.1016/S0166-3542(85)80033-4 Text en © 1985 Elsivier Science Publishers B.V. (Biomedical Division) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hayden, Frederick G. Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title | Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title_full | Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title_fullStr | Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title_full_unstemmed | Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title_short | Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
title_sort | clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134039/ https://www.ncbi.nlm.nih.gov/pubmed/2412490 http://dx.doi.org/10.1016/S0166-3542(85)80033-4 |
work_keys_str_mv | AT haydenfrederickg clinicalapplicationsofantiviralagentsforchemophrophylaxisandtherapyofrespiratoryviralinfections |